Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

Via Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Weiya Yun

Sherrie Lynn Pietranico-Cole

Adrian Wai-Hing Cheung

Yimin Qian

David Robert Bolin

Robert W Guthrie

Paul Gillespie

Nader Fotouhi

Matthew Michael Hamilton

Fariborz Firooznia

Jenny Tan

Lee Apostle McDermott

Stacy W Remiszewski

Robert Francis Kester

Ryan Craig Schoenfeld

Shu-Hai Zhao

Kshitij Chhabilbhai Thakkar

Nicholas J S Huby

Louise H Foley

Peter W Dunten

Yan Lou

Elbert Chin

Kang Le

Norman Kong

Kyungjin Kim

Christophe Michoud

Jing Zhang

Steven Joseph Berthel

Robert James Weikert

John Anthony Moliterni

Xiaochun Han

Andrew Forrest Donnell

Lin Yi

Stuart Hayden

Kenneth Carey Rupert

Lee Aopstle McDermott

Shiming Li

Weiling Liang

Lee Apostle Mcdermott

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Antiviral compounds

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R, R, Rand Rare as described in this application, and methods of using said compounds in the treatment of cancer. 

Indolines

There are provided compounds of the formula 

Substituted hetero-azepinones

Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R, R, Rand Rare as described in this application, and methods of using the compounds in the treatment of cancer. 

Azaindolines

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Inhibitors of diacylglycerol acyltransferase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

Diaminopropionic acid derivatives

The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.

Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors

Growing community of inventors

Warren, NJ, United States of America

Weiya Yun